Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study
| العنوان: | Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
|---|---|
| المؤلفون: | Klaus O, Stumpe, Enrico, Agabiti-Rosei, Tomasz, Zielinski, Dieter, Schremmer, Jürgen, Scholze, Petra, Laeis, Peter, Schwandt, Malte, Ludwig, Uwe, Haag |
| المصدر: | Therapeutic Advances in Cardiovascular Disease. 1:97-106 |
| بيانات النشر: | SAGE Publications, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Adult, Carotid Artery Diseases, Male, medicine.medical_specialty, Angiotensin receptor, Adrenergic beta-Antagonists, Tetrazoles, Pilot Projects, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Humans, Pharmacology (medical), cardiovascular diseases, 030212 general & internal medicine, Aged, Ultrasonography, business.industry, Ultrasound, Imidazoles, Middle Aged, Atenolol, Blockade, Carotid Arteries, Treatment Outcome, Blood pressure, Intima-media thickness, Hypertension, Cardiology, Female, Tunica Intima, Tunica Media, Cardiology and Cardiovascular Medicine, Olmesartan, business, Angiotensin II Type 1 Receptor Blockers, medicine.drug |
| الوصف: | Objective The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensionaL (D) ultrasound (US), to compare the effects of a 2-year treatment based on either olmesartan medoxomil or atenolol on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV). Methods A total of 165 patients (with systolic/diastolic blood pressure 140—180/ 90—105 mmHg) were randomized to receive either olmesartan (20—40 mg/day) or atenolol (50—100 mg/day). US was performed at baseline and 28, 52 and 104 weeks. The primary efficacy outcome was the change from baseline ( Δ) in CC-IMT assessed by 2D US. Secondary outcomes included Δ PV assessed by 3D US and blood pressure (BP). Results Olmesartan and atenolo produced comparable significant reductions in CC-IMT; mean Δ IMT (SEM) was -0.090 (0.015) mm for oLmesartan and -0.082 (0.014) mm for atenolol. Mean Δ PV was -4.4 (2.3) µl and 0.1 (1.5) µl in the olmesartan and atenolol treated subjects, respectively, without significant between-treatment differences. In the subgroup of patients with baseLine PV ≥ median (33.7 µl), significant between-treatment differences existed in Δ PV ( p = 0 .023), because PV regressed significantly with olmesartan ( Δ PV: -11.5 (4.4) µl) but not with atenolol ( Δ PV: 0.6 (2.5) µl). In these patients BP reductions were comparabLe. Conclusions Carotid IMT and BP decreased similarly with olmesartan and atenolol, but only olmesartan reduced the volume of larger atherosclerotic plaques. |
| تدمد: | 1753-9455 1753-9447 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d376f18cadd363cd1b01d40c4ba741Test https://doi.org/10.1177/1753944707085982Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e2d376f18cadd363cd1b01d40c4ba741 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17539455 17539447 |
|---|